Citation: Cortez de Almeida RF, Correia RES, Varón AG, de Oliveira Coelho JMC, de Oliveira AP, Lourenço MCS, et al. (2020) Actinomycetoma with systemic features: A warning sign for immunosuppression? PLoS Negl Trop Dis 14(12): e0008865. https://doi.org/10.1371/journal.pntd.0008865
Editor: Magalie Demar, UNITED STATES
Published: December 3, 2020
Copyright: © 2020 Cortez de Almeida et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Key Learning Points
- Actinomycetoma is a chronic infection usually affecting the subcutaneous tissues of the lower limbs.
- If systemic signs accompany the localized infection, an underlying immunosuppressive condition should be considered.
- The inclusion of mycetoma in the WHO list of neglected diseases will hopefully increase awareness of this neglected disease.
A 32-year-old man was referred to our Dermatology Outpatient Unit with the clinical suspicion of sporotrichosis. At the age of 8, he had suffered a penetrating injury to his right foot, which remained as a painless nodule for years. One year before his outpatient appointment, the nodule progressively increased in size and ulcerated, and in the last 6 months, he began to experience night sweats, a low-grade fever, a 12-kg weight loss, and malaise.
On examination, he had a foul-smelling and painful tumefaction with multiple nodules, fistulae, and purulent discharge, on the medial arch of his right foot (Fig 1A). He was pyrexial (37.9°C), tachycardic (heart rate 126), but otherwise, other physical signs were unremarkable. The differential diagnoses considered for the skin lesion were dermatofibrosarcoma protuberans, amelanotic melanoma, Kaposi’s sarcoma, and actinomycetoma. Exams were performed (biochemistry screen, a full blood count, and a chest X-ray). Amoxicillin clavulanate was initiated, and a punch biopsy of the lesion was done. The patient remained febrile and did not gain weight despite 3 weeks of antibiotics. Chest X-ray showed an enlarged mediastinum (Fig 2A). He was admitted to hospital for further investigation and treatment. Full blood count showed hemoglobin of 5.7 g/dL, 12,250 white blood cells/mm3, and lymphocytes of 2,082 cells/mm3; C-reactive protein was 21.78 mg/L (reference value < 0.3); liver and kidney function tests were normal. Blood cultures and serological tests for HIV, toxoplasmosis, syphilis, cytomegalovirus, and hepatitis B and C were all negative. Because he was unwell and hypotensive on admission, empirical treatment with cotrimoxazole and imipenem was started. Histopathology of the skin biopsy revealed filamentous grain-producing bacteria in hematoxylin and eosin (H&E) stain (Fig 3A). The bacteria stained positive by the Grocott methenamine silver (Fig 3B), Wade, and Gram stains, suggestive of Nocardia spp. Cultures of this fragment in Thayer-Martin and agar-chocolate media showed growth of gram-positive, partially acid-fast bacilli identified as Nocardia spp. (Fig 4) by phenotypic screening tests, such as growth in lysozyme and detection of filamentous growth on coverslip. Molecular identification of the species was obtained by sequencing the polymerase chain reaction product for the hsp65 gene, according to Telenti and colleagues with specific primers (TB11,5′-ACCAACGATGGTGTGTCCAT-3') and (TB12,5′-CTTGTCGAACCGCATACCCT-3′) resulting in the diagnosis of the species Nocardia nova . There were no radiographic signs of bone involvement of the right foot. As part of the investigation of the patient’s general symptoms, which are unusual in actinomycetoma, along with the evidence of mediastinal enlargement seen in the chest X-ray, a computed tomography (CT) scan of the chest was ordered and showed enlarged mediastinal lymph nodes, one with a central hypodensity, and the presence of minimal bilateral pleural effusion (Fig 2B). CT scan of the abdomen showed hepatomegaly and a slightly enlarged spleen. As the patient presented B symptoms and mediastinal lymphadenopathy, a diagnosis of localized actinomycetoma with rapid progression due to an underlying cancer was our main suspicion, followed by a concern of a possible disseminated nocardiosis, which was never documented.
(A) Image obtained on the first day shows tumefaction with multiple nodules, fistulae, and purulent discharge on the medial arch of the right foot. (B) Image obtained following 7 months on cotrimoxazole therapy shows the actinomycetoma healing.
(A) Chest X-rays demonstrate mediastinal enlargement. (B) Computed tomography scan of the chest obtained on the admission shows enlarged mediastinal lymph node, one of them with a central hypodensity and the presence of minimal bilateral pleural effusion.
(A) Ulcerated skin shows filamentous grain intermingled in inflammatory infiltrate. H&E. (B) Numerous radiated filaments emerge from the grain. Grocott methenamine silver stain. H&E, hematoxylin and eosin.
The image shows gram-positive, partially acid-fast, fine, branching filamentous bacilli.
A bone marrow biopsy was done, and microscopy showed 90% of hematopoietic cellularity, normoblastic erythroid series, hyperplastic granulocyte series with normal maturation, and megakaryocytes with normal morphology. There were no granulomas, neoplasia, fungi, or mycobacteria. Bone marrow cultures were negative. A CT-guided mediastinal lymph node biopsy was done, and microscopy showed positive immunohistochemistry for CD30, CD15, and PAX15 and negative for CD3, CD20, and LCA, a classic Nodular Sclerosing Hodgkin’s lymphoma pattern.
Imipenem was stopped after 19 days of treatment; cotrimoxazole was continued and the skin lesion improved (Fig 1B). The patient was referred to a hematology department for the lymphoma treatment, with adriamycin, vinblastine, and dacarbazine. At the 7-month follow-up visit with us, the actinomycetoma was healed; his general health condition consistently improved, he gained 13 kg, and had no fever nor night sweats. The chemotherapy sessions were complete on January 22, 2020, when complete remission was considered, after a positron emission tomography (PET)-CT scan. Cotrimoxazole treatment was maintained until February 13, 2020. A timeline figure helps illustrate some clinical facts (Fig 5).
Mycetoma is a neglected tropical disease; when caused by bacteria, it is named actinomycetoma, and when by fungi, eumycetoma. Nocardia spp. are aerobic filamentous bacteria first recognized as pathogens by Nocard in 1888; they are the main causative agents of actinomycetoma [2–4]. This genus comprises catalase-positive gram-positive rods, which are acid-fast. It produces pale, white, or yellow grains and can be grown on Sabouraud agar . Nocardia spp. have a worldwide distribution, being found in fresh and saltwater, decaying vegetation, and soil. N. nova, nowadays considered a complex of species, is associated with rare cases of actinomycetoma . Infections occur by inhalation or skin trauma, usually resulting in localized infections, mostly in feet, which affect both immunocompetent and immunocompromised patients [3,6]. The typical findings are a triad, which involves painless (or oligosymptomatic) subcutaneous masses, multiple fistulae and grains of different colors, sizes, and consistency, that drain from these fistulae [2,5,6]. This triad points to a few differential diagnoses: botryomycosis, eumycetoma, or actinomycetoma, according to the causative agent (Staphylococcus spp. or other bacteria, filamentous fungi, or aerobic filamentous bacteria, respectively) . The diagnosis of Nocardia spp. infection may go underrecognized because of its relative rarity and its slow growth. Immunosuppressive conditions related to nocardiosis are solid organ and bone marrow transplantation, chronic renal failure, chronic lung disease, HIV/AIDS, cancer, and hematological malignancies. Hematological patients are an at-risk group for nocardiosis due to the intrinsic and therapy-related immunodeficiency [7–8].
We report a case of actinomycetoma with systemic signs, which lead us to investigate an underlying immunosuppression, since such signs are uncommon in this deep and usually localized infection. A literature search of PubMed with the keywords “nocardiosis” and “lymphoma” resulted in 115 articles, of which 10 were cases of primary cutaneous nocardiosis related to hematological malignancies (Table 1) [9–18]. Most cases were reported from the United States; all presented Nocardia spp. infection involving the skin and subcutaneous tissues as a complication of the underlying hematologic condition (after 2 to 24 months, when specified). There is the possibility of latent infection, as in our case, or infection that developed after the malignancy. In the present case, we believe that N. nova had been under immune control, for years, but because of the recent lymphoma-related immunosuppression, control was lost, and the cutaneous lesion flourished. A possible mechanism for the reactivation of the infection is that the anti-inflammatory cytokines interleukin 10 (IL-10) and transforming growth factor beta (TGF-β), produced by Hodgkin’s lymphoma cells, have inhibited the activity of phagocytic cells, thus allowing the proliferation of the N. nova .
The molecular identification of N. nova was late, but it did not compromise the case handling. It is important to emphasize the delay in the diagnosis (around 1 year), which we attribute not only to the limited access of the poorer population to the health system, but also to a low level of suspicion for the diagnosis of actinomycetoma and to an underlying condition. Hopefully, with the inclusion of mycetoma in the WHO list of neglected tropical diseases, this situation in Brazil and in other developing countries may change for the better.
Our strengths are to have been able to clinically suspect and confirm the patient’s diagnosis, as we are a reference institution for infectious diseases, with a good standard routine Microbiology and Pathology laboratories. Secondly, prompt referral to a Cancer Institute led to the diagnosis and treatment of the lymphoma. This case describes the rapid progression of an over 2-decades-old localized actinomycetoma lesion due to an underlying immunosuppressive condition.
All procedures performed were in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments, as well as the Brazilian ethical standards—Resolution (CNS 466/12). Written consent has been obtained from the patient after a full explanation of the purpose and nature of all procedures used. The Institutional Review Board approved the case report under the number 27466619.8.0000.5262.
The authors thank the patient for participating and the staff of the Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, for their care.
- 1. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31(2):175–8. pmid:8381805
- 2. Ahmed AA, van de Sande W, Fahal AH. Mycetoma laboratory diagnosis: Review article. PLoS Negl Trop Dis. 2017;11(8):e0005638. pmid:28837657
- 3. Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb Pathog. 2018;114:369–84. pmid:29146497
- 4. Nocard E. Note sur la maladie des boeufs de la Gouadeloupe connue sous le nom de farcin. Ann Inst Pasteur. 1888;2:293–302.
- 5. Camozzota C, Goldman A, Tchernev G, Lotti T, Wollina U. A Primary Cutaneous Nocardiosis of the Hand. Open Access Maced J Med Sci. 2017;5:470–2. pmid:28785335
- 6. Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19:259–82. pmid:16614249
- 7. Picou A, Batres E, Jarratt M. Botryomycosis: A bacterial cause of mycetoma. Arch Dermatol. 1979;115:609. pmid:443838
- 8. Cattaneo C, Antoniazzi F, Caira M, Castagnola C, Delia M, Tumbarello M, et al. Nocardia spp. infections among hematological patients: results of a retrospective multicenter study. Int J Infect Dis. 2013;17:610–4. pmid:23453714
- 9. Karassik SL, Subramanyam L, Green RE, Brook J. Disseminated Nocardia brasiliensis infection. Arch Dermatol. 1976;112 (3):370–2. pmid:1259450
- 10. Nahas LF, Bennett JE. Nocardiosis of the upper limb. Plast Reconstr Surg. 1981;68:593–5. pmid:7025063
- 11. Wishnitzer R, Berrebi A, Miskin JVD, Frumkin A. Nocardia brasiliensis lymphocutaneous syndrome in a patient with lymphosarcoma. Dermatologica. 1984;169:215–6. pmid:6548715
- 12. Taylor GD, Turner AR. Cutaneous abscess due to Nocardia after "alternative" therapy for lymphoma. CMAJ. 1985;133(8):767. pmid:4042061
- 13. Nishimoto K, Masaki O. Subcutaneous abscesses caused by Nocardia brasiliensis complicated by malignant lymphoma: a survey of cutaneous nocardiosis reported in Japan. Int J Dermatol. 1985;24 (7):437–40. pmid:3877005
- 14. Wlodaver CG, Tolomeo T, Benear JB. Primary Cutaneous Nocardiosis Mimicking Sporotrichosis. Arch Dermatol. 1988;124:659–60. pmid:3284465
- 15. Bath PMW, Pettingale KW, Wade J. Treatment of multiple subcutaneous Nocardia asteroides abscesses with ciprofloxacin and doxycycline. Postgrad Med J. 1989;65:190–1. pmid:2682587
- 16. Shelkovitz-Shilo I, Feinstein A, Trau H, Kaplan B, Sofer E, Schewach-Millet M. Lymphocutaneous nocardiosis due to Nocardia asteroides in a patient with intestinal lymphoma. Int J Dermatol. 1992;31:178–9. pmid:1568812
- 17. Malani AK, Gupta C, Weigand RT, Gupta V, Rangineni S. Thigh abscess due to Nocardia farcinica. J Natl Med Assoc. 2006;98:977–9. pmid:16775924
- 18. Benzaquen M, Belenotti P, Lebowitz D, Drancourt M, Serratrice J. Primary cutaneous nocardiosis caused by Nocardia takedensis with pulmonary dissemination in an immunosuppressed patient. Australas J Dermatol. 2017;58 (3):e97–e100. pmid:27000389
- 19. de la Cruz-Merino L, Lejeune M, Nogales Fernández E, et al. Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol. 2012;2012:756353. pmid:22927872